Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Haemonetics Corporation (NYSE:HAE - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 26,212 shares of the medical instruments supplier's stock, valued at approximately $1,666,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.05% of Haemonetics at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. TD Waterhouse Canada Inc. acquired a new position in shares of Haemonetics during the 4th quarter worth about $25,000. Covestor Ltd lifted its stake in Haemonetics by 146.8% in the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after purchasing an additional 439 shares during the last quarter. KBC Group NV lifted its stake in Haemonetics by 19.9% in the 1st quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock valued at $154,000 after purchasing an additional 401 shares during the last quarter. Vise Technologies Inc. lifted its stake in Haemonetics by 8.7% in the 4th quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock valued at $221,000 after purchasing an additional 225 shares during the last quarter. Finally, CWC Advisors LLC. lifted its stake in Haemonetics by 7.4% in the 4th quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier's stock valued at $241,000 after purchasing an additional 212 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several brokerages recently issued reports on HAE. JMP Securities reiterated a "market outperform" rating and issued a $100.00 target price on shares of Haemonetics in a research note on Tuesday, May 20th. Citigroup upgraded shares of Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 target price for the company in a research note on Wednesday, July 9th. Raymond James Financial reiterated a "strong-buy" rating and issued a $105.00 price target (down from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Wall Street Zen downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Finally, Robert W. Baird initiated coverage on shares of Haemonetics in a research report on Thursday, June 26th. They issued an "outperform" rating and a $87.00 price target for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $97.30.
Get Our Latest Stock Report on Haemonetics
Haemonetics Price Performance
HAE traded up $0.40 during trading on Tuesday, hitting $76.70. 544,642 shares of the stock traded hands, compared to its average volume of 735,456. Haemonetics Corporation has a twelve month low of $55.30 and a twelve month high of $94.99. The company has a market cap of $3.68 billion, a price-to-earnings ratio of 23.17, a PEG ratio of 1.21 and a beta of 0.40. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.62 and a quick ratio of 0.99. The business has a 50 day moving average price of $73.08 and a 200 day moving average price of $67.59.
Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, beating the consensus estimate of $1.22 by $0.02. Haemonetics had a net margin of 12.32% and a return on equity of 26.37%. The business had revenue of $330.60 million during the quarter, compared to the consensus estimate of $329.38 million. During the same period in the previous year, the business earned $0.90 earnings per share. The company's revenue was down 3.5% on a year-over-year basis. Equities research analysts forecast that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.
About Haemonetics
(
Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Further Reading
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access